|
EP3211085B1
(en)
*
|
2003-09-30 |
2021-03-31 |
The Trustees of The University of Pennsylvania |
Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
|
|
US9217155B2
(en)
|
2008-05-28 |
2015-12-22 |
University Of Massachusetts |
Isolation of novel AAV'S and uses thereof
|
|
US8734809B2
(en)
|
2009-05-28 |
2014-05-27 |
University Of Massachusetts |
AAV's and uses thereof
|
|
CA2833912C
(en)
|
2010-04-23 |
2021-09-21 |
University Of Massachusetts |
Aav-based treatment of cholesterol-related disorders
|
|
ES2605305T3
(es)
|
2010-04-23 |
2017-03-13 |
University Of Massachusetts |
Vectores de AAV que se dirigen al SNC y métodos de uso de los mismos
|
|
CA2826273C
(en)
|
2011-02-10 |
2021-11-02 |
The University Of North Carolina At Chapel Hill |
Viral vectors with modified transduction profiles and methods of making and using the same
|
|
JP6224459B2
(ja)
|
2011-02-17 |
2017-11-01 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
組織特異性を改変し、ａａｖ９媒介遺伝子導入を改善するための組成物および方法
|
|
EP3318634A1
(en)
|
2011-04-21 |
2018-05-09 |
University of Massachusetts |
Raav-based compositions and methods for treating diseases involving dominant-negative or gain of function mutations
|
|
EP2847337A4
(en)
*
|
2012-05-09 |
2016-04-27 |
Univ Oregon Health & Science |
ADENO ASSOCIATED VIRUS PLASMIDS AND VECTORS
|
|
EP2749569A1
(en)
|
2012-12-28 |
2014-07-02 |
Annibale Alessandro Puca |
Variant of BPIFB4 protein
|
|
US20140219964A1
(en)
|
2013-02-07 |
2014-08-07 |
Children's Medical Center Corporation |
Methods for inducing cardiomyocyte proliferation
|
|
CA2905952A1
(en)
*
|
2013-03-13 |
2014-10-02 |
The Children's Hospital Of Philadelphia |
Adeno-associated virus vectors and methods of use thereof
|
|
CN110885854A
(zh)
*
|
2013-03-15 |
2020-03-17 |
北卡罗来纳-查佩尔山大学 |
双重聚糖结合aav载体的方法和组合物
|
|
PL2984166T3
(pl)
|
2013-03-15 |
2021-01-11 |
The Trustees Of The University Of Pennsylvania |
Kompozycje do leczenia mpsi
|
|
CN115252823A
(zh)
|
2014-03-21 |
2022-11-01 |
建新公司 |
用于色素性视网膜炎的基因疗法
|
|
US10746742B2
(en)
|
2014-04-25 |
2020-08-18 |
Oregon Health & Science University |
Methods of viral neutralizing antibody epitope mapping
|
|
US10689653B2
(en)
|
2014-06-03 |
2020-06-23 |
University Of Massachusetts |
Compositions and methods for modulating dysferlin expression
|
|
EP3151866B1
(en)
|
2014-06-09 |
2023-03-08 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
|
PL4012035T3
(pl)
|
2014-09-16 |
2025-03-24 |
Genzyme Corporation |
Wektory wirusowe związane z adenowirusami do leczenia jaskry miocylinowej (myoc)
|
|
EP4012035B1
(en)
|
2014-09-16 |
2024-11-06 |
Genzyme Corporation |
Adeno-associated viral vectors for treating myocilin (myoc) glaucoma
|
|
US10370432B2
(en)
|
2014-10-03 |
2019-08-06 |
University Of Massachusetts |
Heterologous targeting peptide grafted AAVS
|
|
US10711270B2
(en)
|
2014-10-03 |
2020-07-14 |
University Of Massachusetts |
High efficiency library-identified AAV vectors
|
|
CN107073051B
(zh)
|
2014-10-21 |
2021-08-24 |
马萨诸塞大学 |
重组aav变体及其用途
|
|
SG10202007103TA
(en)
|
2014-11-05 |
2020-09-29 |
Voyager Therapeutics Inc |
Aadc polynucleotides for the treatment of parkinson's disease
|
|
MX2017006216A
(es)
|
2014-11-14 |
2018-08-29 |
Voyager Therapeutics Inc |
Composiciones y métodos para tratar la esclerosis lateral amiotrófica (ela).
|
|
IL284949B2
(en)
|
2014-11-14 |
2024-06-01 |
Voyager Therapeutics Inc |
Modulatory polynucleotides
|
|
WO2016094783A1
(en)
|
2014-12-12 |
2016-06-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the production of scaav
|
|
IL296391B2
(en)
|
2015-01-20 |
2024-06-01 |
Genzyme Corp |
Analytical ultracentrifugation for characterization of recombinant viral particles
|
|
WO2016130591A2
(en)
|
2015-02-10 |
2016-08-18 |
Genzyme Corporation |
Enhanced delivery of viral particles to the striatum and cortex
|
|
JP2018506304A
(ja)
|
2015-02-10 |
2018-03-08 |
ジェンザイム・コーポレーション |
バリアントＲＮＡｉ
|
|
US10584321B2
(en)
|
2015-02-13 |
2020-03-10 |
University Of Massachusetts |
Compositions and methods for transient delivery of nucleases
|
|
TWI707951B
(zh)
|
2015-04-08 |
2020-10-21 |
美商健臻公司 |
過大腺相關載體之製造
|
|
US11046955B2
(en)
|
2015-04-24 |
2021-06-29 |
University Of Massachusetts |
Modified AAV constructs and uses thereof
|
|
CA2986021A1
(en)
|
2015-05-16 |
2016-11-24 |
Genzyme Corporation |
Gene editing of deep intronic mutations
|
|
WO2017019876A1
(en)
*
|
2015-07-28 |
2017-02-02 |
University Of Massachusetts |
Transgenic expression of dnase i in vivo delivered by an adeno-associated virus vector
|
|
WO2017070516A1
(en)
|
2015-10-22 |
2017-04-27 |
University Of Massachusetts |
Prostate-targeting adeno-associated virus serotype vectors
|
|
EP3364997B1
(en)
|
2015-10-22 |
2024-01-17 |
University of Massachusetts |
Aspartoacylase gene therapy in the treatment of canavan disease
|
|
WO2017096162A1
(en)
|
2015-12-02 |
2017-06-08 |
Voyager Therapeutics, Inc. |
Assays for the detection of aav neutralizing antibodies
|
|
US11098286B2
(en)
|
2015-12-11 |
2021-08-24 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for AAV9
|
|
WO2017100704A1
(en)
|
2015-12-11 |
2017-06-15 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aavrh10
|
|
WO2017100674A1
(en)
|
2015-12-11 |
2017-06-15 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aav1
|
|
EP3387117B1
(en)
|
2015-12-11 |
2022-11-23 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aav8
|
|
AU2016372035B2
(en)
|
2015-12-15 |
2023-03-30 |
Genzyme Corporation |
Adeno-associated viral vectors for treating mucolipidosis type ii
|
|
WO2017136536A1
(en)
|
2016-02-02 |
2017-08-10 |
University Of Massachusetts |
Method to enhance the efficiency of systemic aav gene delivery to the central nervous system
|
|
SG11201806270XA
(en)
|
2016-02-03 |
2018-08-30 |
Univ Pennsylvania |
Gene therapy for treating mucopolysaccharidosis type i
|
|
WO2017139643A1
(en)
|
2016-02-12 |
2017-08-17 |
University Of Massachusetts |
Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
|
|
EP3440210A4
(en)
|
2016-04-05 |
2019-11-27 |
University of Massachusetts |
COMPOSITIONS AND METHOD FOR SELECTIVELY INHIBITING THE EXPRESSION OF GRAINYHEAD LIKE PROTEIN
|
|
US11413356B2
(en)
|
2016-04-15 |
2022-08-16 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance
|
|
KR20190008237A
(ko)
|
2016-04-15 |
2019-01-23 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
Ii형 점액다당류증의 치료를 위한 유전자 요법
|
|
US11299751B2
(en)
|
2016-04-29 |
2022-04-12 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
|
EP3448874A4
(en)
|
2016-04-29 |
2020-04-22 |
Voyager Therapeutics, Inc. |
COMPOSITIONS FOR TREATING A DISEASE
|
|
RU2725286C2
(ru)
|
2016-05-13 |
2020-06-30 |
4Д Молекьюлар Терапьютикс Инк. |
Варианты капсидов аденоассоциированного вируса и способы их применения
|
|
AU2017268382B2
(en)
|
2016-05-18 |
2023-09-28 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating Huntington's disease
|
|
EP3458588B1
(en)
|
2016-05-18 |
2025-10-29 |
Voyager Therapeutics, Inc. |
Modulatory polynucleotides
|
|
US11882815B2
(en)
|
2016-06-15 |
2024-01-30 |
University Of Massachusetts |
Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
|
|
CN106093369B
(zh)
*
|
2016-06-29 |
2017-10-20 |
福建农林大学 |
Bt水稻对非靶标害虫褐飞虱的安全性评价方法
|
|
US11698377B2
(en)
|
2016-08-15 |
2023-07-11 |
Genzyme Corporation |
Methods for detecting AAV
|
|
US11298041B2
(en)
|
2016-08-30 |
2022-04-12 |
The Regents Of The University Of California |
Methods for biomedical targeting and delivery and devices and systems for practicing the same
|
|
US10457940B2
(en)
|
2016-09-22 |
2019-10-29 |
University Of Massachusetts |
AAV treatment of Huntington's disease
|
|
KR20190075964A
(ko)
|
2016-10-13 |
2019-07-01 |
유니버시티 오브 매사추세츠 |
Aav 캡시드 설계
|
|
WO2018119330A2
(en)
*
|
2016-12-22 |
2018-06-28 |
Oregon Health & Science University |
Adeno associated viral vectors
|
|
EP3618839A4
(en)
|
2017-05-05 |
2021-06-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (als)
|
|
CN111108198A
(zh)
|
2017-05-05 |
2020-05-05 |
沃雅戈治疗公司 |
治疗亨廷顿病的组合物和方法
|
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
|
KR20200053468A
(ko)
|
2017-07-06 |
2020-05-18 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
I형 점액다당류증을 치료하기 위한 유전자 요법
|
|
AU2018302016A1
(en)
|
2017-07-17 |
2020-02-06 |
The Regents Of The University Of California |
Trajectory array guide system
|
|
MX2020003176A
(es)
|
2017-09-20 |
2020-08-20 |
4D Molecular Therapeutics Inc |
Variantes de capsides de virus adenoasociados y metodos de uso de estas.
|
|
AR113134A1
(es)
|
2017-09-22 |
2020-01-29 |
Genzyme Corp |
Arni variante
|
|
WO2019060662A1
(en)
|
2017-09-22 |
2019-03-28 |
The Trustees Of The University Of Pennsylvania |
GENE THERAPY FOR THE TREATMENT OF MUCOPOLYSACCHARIDOSE TYPE II
|
|
EP3687582A4
(en)
|
2017-09-29 |
2021-07-14 |
Voyager Therapeutics, Inc. |
RESCUE OF CENTRAL AND PERIPHERAL NEUROLOGICAL PHENOTYPE OF FRIEDREICH ATAXIA BY INTRAVENOUS ADMINISTRATION
|
|
WO2019079242A1
(en)
|
2017-10-16 |
2019-04-25 |
Voyager Therapeutics, Inc. |
TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
|
|
CN111479924B
(zh)
|
2017-10-16 |
2024-06-14 |
沃雅戈治疗公司 |
肌萎缩性侧索硬化症(als)的治疗
|
|
CA3083472A1
(en)
|
2017-11-27 |
2019-05-31 |
4D Molecular Therapeutics Inc. |
Adeno-associated virus variant capsids and use for inhibiting angiogenesis
|
|
PE20210341A1
(es)
*
|
2018-02-01 |
2021-02-23 |
Homology Medicines Inc |
Composiciones de virus adeno-asociadas para la transferencia de genes pah y metodos de uso de los mismos
|
|
PE20212076A1
(es)
|
2018-02-01 |
2021-10-26 |
Homology Medicines Inc |
Composiciones de virus adeno-asociado para restaurar la funcion del gen pah y metodos de uso de las mismas
|
|
US10610606B2
(en)
|
2018-02-01 |
2020-04-07 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
|
|
CN112041437A
(zh)
|
2018-02-19 |
2020-12-04 |
同源药物公司 |
用于恢复f8基因功能的腺相关病毒组合物和其使用方法
|
|
EP3775173A1
(en)
|
2018-04-05 |
2021-02-17 |
Genethon |
Hybrid recombinant adeno-associated virus serotype between aav9 and aavrh74 with reduced liver tropism
|
|
WO2019204303A2
(en)
|
2018-04-16 |
2019-10-24 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treating duchenne muscular dystrophy
|
|
WO2019213668A1
(en)
*
|
2018-05-04 |
2019-11-07 |
Oregon Health & Science University |
Human anti-aav2 capsid polyclonal antibody epitopes
|
|
MA52631A
(fr)
|
2018-05-15 |
2021-03-24 |
Voyager Therapeutics Inc |
Compositions et méthodes pour le traitement de la maladie de parkinson
|
|
US12163129B2
(en)
|
2018-06-08 |
2024-12-10 |
University Of Massachusetts |
Antisense oligonucleotides to restore dysferlin protein expression in dysferlinopathy patient cells
|
|
WO2019241486A1
(en)
|
2018-06-13 |
2019-12-19 |
Voyager Therapeutics, Inc. |
Engineered 5' untranslated regions (5' utr) for aav production
|
|
JP2021530548A
(ja)
|
2018-07-24 |
2021-11-11 |
ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics, Inc. |
遺伝子治療製剤を生産するための系および方法
|
|
PH12021550254A1
(en)
|
2018-08-03 |
2023-02-06 |
Genzyme Corp |
Variant rnai against alpha-synuclein
|
|
JP7528066B2
(ja)
|
2018-09-28 |
2024-08-05 |
ボイジャー セラピューティクス インコーポレイテッド |
操作されたプロモータを有するフラタキシン発現コンストラクトおよびその使用方法
|
|
EP3861113A1
(en)
|
2018-10-04 |
2021-08-11 |
Voyager Therapeutics, Inc. |
Methods for measuring the titer and potency of viral vector particles
|
|
CA3115248A1
(en)
|
2018-10-05 |
2020-04-09 |
Voyager Therapeutics, Inc. |
Engineered nucleic acid constructs encoding aav production proteins
|
|
EP3863662A1
(en)
|
2018-10-12 |
2021-08-18 |
Genzyme Corporation |
Generation of improved human pah for treatment of severe pku by liver-directed gene replacement therapy
|
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
|
TW202028468A
(zh)
|
2018-10-15 |
2020-08-01 |
美商航海家醫療公司 |
用於桿狀病毒/Sf9系統中rAAV之大規模生產的表現載體
|
|
EP3917566A4
(en)
|
2019-01-31 |
2022-10-26 |
Oregon Health & Science University |
METHODS OF USING TRANSCRIPTION-DEPENDENT DIRECTED EVOLUTION OF AAV CAPSIDS
|
|
WO2020174369A2
(en)
|
2019-02-25 |
2020-09-03 |
Novartis Ag |
Compositions and methods to treat bietti crystalline dystrophy
|
|
JP2022521025A
(ja)
|
2019-02-25 |
2022-04-04 |
ノバルティス アーゲー |
Ｂｉｅｔｔｉクリスタリン網膜症を治療するための組成物及び方法
|
|
CN113557010A
(zh)
|
2019-02-28 |
2021-10-26 |
瑞泽恩制药公司 |
用于递送治疗剂的腺相关病毒载体
|
|
US12398378B2
(en)
|
2019-04-12 |
2025-08-26 |
University Of Massachusetts |
AAV-mediated gene therapy for maple syrup urine disease (MSUD)
|
|
AU2020278960A1
(en)
*
|
2019-05-17 |
2021-12-23 |
Research Institute At Nationwide Children's Hospital |
Optimized gene therapy targeting retinal cells
|
|
US10653731B1
(en)
|
2019-07-15 |
2020-05-19 |
Vigene Biosciences Inc. |
Recombinantly-modified adeno-associated virus (rAAV) having improved packaging efficiency
|
|
US10557149B1
(en)
|
2019-07-15 |
2020-02-11 |
Vigene Biosciences, Inc. |
Recombinantly-modified adeno-associated virus helper vectors and their use to improve the packaging efficiency of recombinantly-modified adeno-associated virus
|
|
US10801042B1
(en)
|
2019-07-15 |
2020-10-13 |
Vigene Biosciences, Inc. |
Use of ion concentrations to increase the packaging efficiency of recombinant adeno-associated virus
|
|
AU2020367532A1
(en)
*
|
2019-10-17 |
2022-05-12 |
Ginkgo Bioworks, Inc. |
Adeno-associated viral vectors for treatment of Niemann-Pick disease type C
|
|
CA3159620A1
(en)
*
|
2019-11-01 |
2021-05-06 |
Sangamo Therapeutics, Inc. |
Compositions and methods for genome engineering
|
|
TW202140791A
(zh)
|
2020-01-13 |
2021-11-01 |
美商霍蒙拉奇醫藥公司 |
治療苯酮尿症之方法
|
|
TW202208632A
(zh)
|
2020-05-27 |
2022-03-01 |
美商同源醫藥公司 |
用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法
|
|
WO2022051468A1
(en)
|
2020-09-04 |
2022-03-10 |
Milwaukee Electric Tool Corporation |
Chainsaw
|
|
MX2023003805A
(es)
|
2020-10-01 |
2023-04-12 |
Genzyme Corp |
Casete de expresion de pah humana para el tratamiento de la pku mediante terapia de reemplazo genico dirigida al higado.
|
|
US20240091380A1
(en)
|
2021-02-01 |
2024-03-21 |
Regenxbio Inc. |
Gene therapy for neuronal ceroid lipofuscinoses
|
|
WO2023010135A1
(en)
|
2021-07-30 |
2023-02-02 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
|
|
EP4377459A2
(en)
|
2021-07-30 |
2024-06-05 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of frataxin (fxn)
|
|
US20250144243A1
(en)
*
|
2022-01-25 |
2025-05-08 |
The Trustees Of The University Of Pennsylvania |
Aav capsids for improved heart transduction and detargeting of liver
|
|
KR20250007619A
(ko)
|
2022-05-06 |
2025-01-14 |
노파르티스 아게 |
신규 재조합 aav vp2 융합 폴리펩티드
|
|
WO2024015881A2
(en)
|
2022-07-12 |
2024-01-18 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for targeted transcriptional activation
|
|
WO2024163683A2
(en)
|
2023-02-01 |
2024-08-08 |
Tune Therapeutics, Inc. |
Systems, compositions, and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) and x-inactive specific transcript (xist)
|
|
WO2024163678A2
(en)
|
2023-02-01 |
2024-08-08 |
Tune Therapeutics, Inc. |
Fusion proteins and systems for targeted activation of frataxin (fxn) and related methods
|
|
TW202509211A
(zh)
|
2023-04-26 |
2025-03-01 |
法商賽諾菲公司 |
宿主細胞系以及鑑定和使用該等宿主細胞系之方法
|
|
US20250197862A1
(en)
|
2023-12-15 |
2025-06-19 |
Genzyme Corporation |
ARTIFICIAL microRNAs TARGETING TAU
|
|
WO2025160434A1
(en)
|
2024-01-26 |
2025-07-31 |
Genzyme Corporation |
Artificial micrornas targeting huntington's disease
|
|
WO2025160429A1
(en)
|
2024-01-26 |
2025-07-31 |
Genzyme Corporation |
Artificial micrornas targeting snca
|
|
WO2025188755A1
(en)
|
2024-03-04 |
2025-09-12 |
Kate Therapeutics, Inc. |
Adeno-associated virus compositions for the treatment of duchenne muscular dystrophy
|
|
WO2025226841A1
(en)
|
2024-04-24 |
2025-10-30 |
Kate Therapeutics, Inc. |
Gene therapy approach for treating disorders associated with tnnt2
|
|
WO2025226842A1
(en)
|
2024-04-24 |
2025-10-30 |
Kate Therapeutics, Inc. |
Expression control by drg-expressed mirnas
|
|
WO2026011008A1
(en)
|
2024-07-02 |
2026-01-08 |
Kate Therapeutics, Inc. |
Expression control by skeletal muscle-expressed mirnas
|
|
WO2026011009A1
(en)
|
2024-07-02 |
2026-01-08 |
Kate Therapeutics, Inc. |
Compositions and methods for muscle disorders
|